EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer

Area of Science:

• Molecular biology
• Oncology
• Biochemistry

Background:

• Somatic mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain are linked to gefitinib response in non-small-cell lung carcinoma (NSCLC).
• Understanding the mechanism of EGFR activation by these mutations is crucial for developing effective cancer treatments.

Purpose of the Study:

• To investigate whether identified EGFR mutations lead to constitutive signaling.
• To elucidate the biochemical basis of EGFR activation by oncogenic mutations.
• To explore the role of specific mutations in EGFR autoinhibition disruption.

Main Methods:

• Expression of representative EGFR mutations in a null background.
• Biochemical analysis of mutant EGFRs, including tyrosine phosphorylation and mitogenic signaling assays.
• Assessment of EGF binding and receptor localization.

Main Results:

• All tested EGFR mutations induced significant EGF-independent tyrosine phosphorylation and Ba/F3 cell mitogenesis.
• Mutated EGFRs are cell surface-expressed and retain EGF binding capacity.
• Mutations predicted to disrupt intramolecular autoinhibition enhance EGF-independent kinase activity.

Conclusions:

• The studied EGFR mutations are oncogenic, causing constitutive receptor activation.
• Disruption of EGFR autoinhibition is a key mechanism for oncogenic activation.
• Findings provide mechanistic insights into EGFR and ErbB family member activation by somatic mutations.